Szingapúr - angol - HSA (Health Sciences Authority)

mundipharma pharmaceuticals pte. ltd. - prednisone - tablet, delayed release - 5.00mg/tablet

Kanada - angol - Health Canada

contract packaging resources inc,a member of the aenova group - docusate sodium - capsule - 100mg - docusate sodium 100mg - cathartics and laxatives

Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mundipharma pharmaceuticals sdn. bhd. - prednisone; prednisone -

Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mundipharma pharmaceuticals sdn. bhd. - prednisone; prednisone -

Malajzia - angol - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mundipharma pharmaceuticals sdn. bhd. - prednisone; prednisone -

Kanada - angol - Health Canada

apotex inc - meloxicam - suspension - 1.5g - meloxicam 1.5g - dogs

Jordánia - angol - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة العربية للمستحضرات الطبية والزراعية - arab company for medical & agricultural products - hydrocortisone butyrate 1 mg/g - 1 mg/g

Málta - angol - Medicines Authority

omega pharma limited 1st floor, 32 vauxhall bridge road, london sw1v 2sa, united kingdom - codeine phosphate, hemihydrate, ibuprofen - film-coated tablet - codeine phosphate hemihydrate 12.8 mg ibuprofen 200 mg - antiinflammatory and antirheumatic products

Málta - angol - Medicines Authority

omega pharma limited - caffeine, paracetamol, codeine phosphate, hemihydrate - capsule - caffeine 30 milligram(s) ; paracetamol 500 milligram(s) ; codeine phosphate hemihydrate 8 milligram(s) - analgesics

Egyesült Államok - angol - NLM (National Library of Medicine)

shionogi inc. - fenofibrate (unii: u202363uos) (fenofibrate - unii:u202363uos) - fenofibrate 160 mg - triglide is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides, and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. triglide is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g., >2,000 mg/dl) may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes